Gao, Leili

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023) · Nature Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 104

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., et al. (2022) · eClinicalMedicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 83

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Ji, L., Gao, L., Xue, H., Tian, J., Wang, K., Jiang, H., Huang, C., Lian, Q., Yuan, M., Gao, G., et al. (2025) · The Lancet Diabetes & Endocrinology

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 35

A comparison of daily glucose fluctuation between GCK-MODY and type 2 diabetes using continuous glucose monitoring technology

Ren, Q., Zhang, P., Pang, W., Ma, Y., Gong, S., Ba, T., Liu, W., Zhang, F., Zhang, X., Zhang, R., et al. (2023) · Diabetes

Diabetes Management and ResearchPancreatic function and diabetes

Cited by 14